Viking Therapeutics Shares Surge Up to 39% on Positive Weight-Loss Drug Maintenance Data
The field of Biotech haunts its very own investors from the very fact that it attracts them, the potential effectiveness of their drug in achieving actual recovery and the eventual reduction in the number of shots necessary for patients. In trials, weekly injections often curate a promising picture, but in many real-life plaguing conditions like obesity, the weekly program results aren't likely to last forever..
Read More
.jpg)
